Word

HUMABODY

Status

Registered

Status Code

700

Status Date

Tuesday, May 30, 2023

Serial Number

79332232

Registration Number

7064382

Registration Date

Tuesday, May 30, 2023

Mark Type

5000

Filing Date

Thursday, August 12, 2021

Published for Opposition

Tuesday, March 14, 2023

Trademark Owner History

Crescendo Biologics Limited - Original Registrant

Classifications

40 Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services

5 Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; pharmaceutical preparations for use in oncology; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto

1 Chemicals used in industry and science; Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products

45 Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services

42 Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory research services relating to the development of antibodies and antibody fragments; oncological research; research into the development of antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services

The mark consists of the wording "HUMABODY" in a stylized font.

Trademark Events

Oct 27, 2023

Limitation From The Ib Examined, No Action Is Needed

Sep 25, 2023

Final Decision Transaction Processed By Ib

Aug 31, 2023

Final Disposition Notice Sent To Ib

Aug 31, 2023

Final Disposition Processed

Aug 30, 2023

Final Disposition Notice Created, To Be Sent To Ib

Aug 19, 2023

Restriction Of Holder's Right Of Disposal Received

May 30, 2023

Notice Of Registration Confirmation Emailed

May 30, 2023

Registered-Principal Register

Mar 15, 2023

Notification Processed By Ib

Mar 14, 2023

Official Gazette Publication Confirmation E-Mailed

Mar 14, 2023

Published For Opposition

Feb 22, 2023

Notification Of Possible Opposition Sent To Ib

Feb 22, 2023

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Feb 22, 2023

Notification Of Notice Of Publication E-Mailed

Feb 6, 2023

Approved For Pub - Principal Register

Feb 3, 2023

Examiner's Amendment Entered

Feb 3, 2023

Notification Of Examiners Amendment E-Mailed

Feb 3, 2023

Examiners Amendment E-Mailed

Feb 3, 2023

Examiners Amendment -Written

Dec 16, 2022

Notification Of Final Refusal Emailed

Dec 16, 2022

Final Refusal E-Mailed

Dec 16, 2022

Final Refusal Written

Nov 15, 2022

Preliminary/Voluntary Amendment - Entered

Nov 15, 2022

Teas Voluntary Amendment Received

Oct 28, 2022

Teas/Email Correspondence Entered

Oct 28, 2022

Correspondence Received In Law Office

Oct 28, 2022

Teas Response To Office Action Received

Oct 14, 2022

Correction From Ib Entered - Attorney Review Required

Jul 13, 2022

Refusal Processed By Ib

Jul 10, 2022

Correction Transaction Received From Ib

Jun 16, 2022

Non-Final Action Mailed - Refusal Sent To Ib

Jun 16, 2022

Refusal Processed By Mpu

May 24, 2022

Non-Final Action (Ib Refusal) Prepared For Review

May 23, 2022

Non-Final Action Written

May 13, 2022

Assigned To Examiner

Feb 8, 2022

Application Filing Receipt Mailed

Feb 4, 2022

New Application Office Supplied Data Entered

Feb 3, 2022

Sn Assigned For Sect 66a Appl From Ib